1.
|
8 p, 257.6 KB |
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
/
Prat, A. (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Parker, J. S. (University of North Carolina. Lineberger Comprehensive Cancer Center) ;
Fan, C. (LUniversity of North Carolina. Lineberger Comprehensive Cancer Center) ;
Cheang, M. C. U. (University of North Carolina. Lineberger Comprehensive Cancer Center) ;
Miller, L. D. (Wake Forest School of Medicine. Department of Cancer Biology) ;
Bergh, Jonas (Manchester University. Department of Medical Oncology) ;
Chia, S. K. L. (British Columbia Cancer Agency) ;
Bernard, P. S. (University of Utah Health Sciences Center. Department of Pathology) ;
Nielsen, T. O. (University of British Columbia. Department of Pathology) ;
Ellis, M. J. (Siteman Cancer Center at Washington University. Department of Medicine) ;
Carey, L. A. (University of North Carolina. Deparment of Medicine) ;
Perou, Charles M. (University of North Carolina. Pathology & Laboratory Medicine)
ER-positive (ER+) breast cancer includes all of the intrinsic molecular subtypes, although the luminal A and B subtypes predominate. In this study, we evaluated the ability of six clinically relevant genomic signatures to predict relapse in patients with ER+ tumors treated with adjuvant tamoxifen only. [...]
2012 - 10.1093/annonc/mds080
Annals of oncology, Vol. 23 Núm. 11 (november 2012) , p. 2866-2873
|
|
2.
|
12 p, 915.6 KB |
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers
/
Bastien, Roy R. L. (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Rodríguez-Lescure, Álvaro (Hospital General Universitario de Elche) ;
Ebbert, Mark T. W. (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Prat, Aleix (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Munárriz, Blanca (Hospital Universitari i Politècnic La Fe (València)) ;
Rowe, Leslie (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Miller, Patricia (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Ruiz Borrego, Manuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Anderson, Daniel (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Lyons, Bradley (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Álvarez López, Isabel (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ;
Dowell, Tracy (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Wall, David (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Seguí, Miguel Ángel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Barley, Lee (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Boucher, Kenneth M. (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ;
Alba, Emilio (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Pappas, Lisa (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ;
Davis, Carole A. (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ;
Aranda, Ignacio (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Fauron, Christiane (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Stijleman, Inge J. (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ;
Palacios, José (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Antón, Antonio (Hospital Universitario Miguel Servet (Saragossa)) ;
Carrasco, Eva (GEICAM. Spanish Breast Cancer Research Group (Madrid)) ;
Caballero, Rosalía (GEICAM. Spanish Breast Cancer Research Group (Madrid)) ;
Ellis, Matthew J. (Washington University. Department of Oncology (St. Louis, Estats Units d'Amèrica)) ;
Nielsen, Torsten O. (University of British Columbia. Department of Anatomical Pathology (Vancouver, Canadà)) ;
Perou, Charles M. (University of North Carolina at Chapel Hill. Lineberger Comprehensive Cancer Center (Chapel Hill, Estats Units d'Amèrica)) ;
Astill, Mark (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Bernard, Philip S. (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ;
Martín Jiménez, Miguel (Hospital General Universitario Gregorio Marañón)
Background: Many methodologies have been used in research to identify the "intrinsic" subtypes of breast cancer commonly known as Luminal A, Luminal B, HER2-Enriched (HER2-E) and Basal-like. The PAM50 gene set is often used for gene expression-based subtyping; however, surrogate subtyping using panels of immunohistochemical (IHC) markers are still widely used clinically. [...]
2012 - 10.1186/1755-8794-5-44
BMC medical genomics, Vol. 15, N. 44 (October 2012) , p. 1-9
4 documents
|
|